INCREASING attention has been paid in recent years to the role of blood coagulation and fibrinolysis in relation to the general problem of atherosclerosis. This has been in part due to the revival of the concept, still controversial, that atheromatous plaques may originate in fibrin deposits.'-5 Moreover, recent work in pathologic>9 and epidemiologic'0 fields points to a disparity between the incidence of atherosclerotic lesions on the one hand and arterial thromboses on the other. This latter evidence would suggest that thrombosis in the course of atherosclerosis may not be purely a phenomenon secondary to the surface effect of the atheromatous lesion. Yet, surface characteristics are known to affect the velocity of blood coagulation," aiid from the surface properties of the atheromatous lesion,12 it would appear reasonable to assume that the relatively high incidence of arterial thrombosis associated with atherosclerotic disease is at least partly due to some effect of a diseased arterial wall on the blood coagulation mechanism. To ascertain whether the passa.ge of blood over a diseased arterial wall does indeed affect its coagulation activity it was thought that a comparative study of the coagulation and fibrinolytic characteristies of the arterial and venous blood in patients with atherosclerosis might be instructive; particularly if it were contrasted with a similar study in normal subjects. This study appeared especially worth while, since-in studies of blood coagulation and fibrinolysis as related to atherosclerosis, few investigations of the arterial blood have been reported; and yet atherosclerotic lesions are confined to the arterial systeni. Furthermore, the question of changes in blood coagulation of patients with atherosclerosis, based on the studies only of the venous blood has been a subject of controversy in the literature. '3 In an effort to help resolve this controversy, it was thought a comparative study of the coagulation activity of the venous blood in patients with atherosclerotic disease and that of a control group could also be usefully included in this study.
Materials and Methods
The investigations were carried out in two phases. This was necessary in view of the inherent difficulty in selection of suitable control groups in the studies of this nature. 13 Because of this it was decided to have two different control groups in the two phases of these investigations. Phase 1. All the subjects studied in this phase of the investigations are designated as series A. In this phase we were interested to find out whether the passage of blood over a diseased arterial wall affected its coagulation and fibrinolytie activities. To evaluate this, we had to find out in the first place, what differences, if any, exist between the coagulation characteristics of the arterial and venous blood in the normal subject. We therefore required a control group composed of relatively young subjects, in whom we could assume relative freedom from atherosclerosis. In the older age group, it would not be justifiable to assume this to be the case even in the absence of clinical manifestations of atherosclerosis. [14] [15] [16] For this reason the control group selected for this phase of the studv was vounger than the group with atheroselerosis. Tn view of this difference in the age composition of the two groups, however, the coagulation data obtained in this phase of the study were used only to evaluate the Circulation, Volume XXVII, May 1963 arteriovenous differences in the same group where each subject acted as his own control; the data were not used to compare the control subjects with the patients. The data obtained in the fibrinolytic studies, on the other hand, were used for both types of statistical comparison; since observations in our laboratory, as well as those of other investigators,17 have indicated no change in blood fibrinolysis with increasing age. The control group in this phase of the study consisted of 28 subjects, 16 male and 12 female, composed of young members of the hospital staff and relatively young in-patients, who had no systemic disease that might have interfered with studies of blood coagulation and fibrinolysis. The patient group was composed of 68 in-patients, 42 male and 26 female, with evidence of atherosclerotic disease as manifested by coronary heart disease (angina pectoris or old nmyocardial infaretion or both or occlusive disease of the peripheral arteries). The average age of the control group was 27 years, with a range of 19 to 42 years; that of the patients was 56 years, with a range of 31 to 82 years.
Studies of the coagulation activity of arterial and venous blood were carried out simultaneously on the first 16 control subjects and the first 20 patients with coronary heart disease. Studies of the fibrinolytic activity of arterial and venous blood were carried out simultaneously on all the subjects in this phase of the study, except when satisfactory arterial blood was not obtained. For this reason there are fewer arterial results coinpared with the venous, (28 venous and 24 arterial fibrinolysis results in control subjects, and 68 venous and 56 arterial in patients). In the statistical analysis of arteriovenous differences, however, only paired arterial and venous data were used.
Phase II. All the subjects studied in this phase of the investigations are designated as series B. In this phase we were interested in the evaluation of the possible changes in the coagulation activity of the venous blood in patients with coronary heart disease conlpared to matched controls with no apparent evidence of atherosclerosis. There were 19 subjects, 14 nlale and 5 female, in each group in this phase of the study. The average age of the control subjects was 50 years, with a range of 28 to 71 years, and that of the patients with coronary heart disease was 52 years, with a range of 27 to 69 years (the small difference was not statistically significant). Blood coagulation was investigated simultaneously in each patient and his or her matched control.
In selecting patients for these investigations, care was taken to exclude those with clinical evidence of recent vascular occlusion. The subjects Circulation, Volume XXVII, May 1963 were instructed to fast after 10:00 P.M., and care was taken to collect the blood sam-ples between 9:00 and 9:30 A.M. on the following morning. This schedule was adopted to eliminate differences that might be attributable to the reported diurnal variation in fibrinolytic activity,'7-19 and to rule out the possible effect of postprandial lipemia.20 Blood was withdrawn with a 19-gage siliconized needle and syringe by arterial and venous puncture from the brachial artery of one arm and the antecubital vein of the other armi, with use of a 2-syringe technic.
Coagulation Methods
Anticoagulant. Three per cent sodium citrate was used as the anticoagulant throughout. In the collection of blood for the coagulation studies, nine volumes of blood were added to one volume of citrate.
Prothrombin time. The method of Quick was used except that a saline extract of acetone-dried human brain was used as a source of thromboplastin.
Prothrombin level. Plasma prothrombin was quantitatively determined by a modification of the Owren technic as described by Alexander.21 Factor V (labile factor). Activity was ineasured by determining the corrective effect on the prothrombin time of a substrate devoid of factor V, but containing the other factors (prothroimibin, factor VII and X, and fibrinogen) that affect the prothrombin time,22 a modification of the Owren technic.
Factor VII and X activity. The procedure used was a modification of the Owren technic for determining proconvertin activity.23 This technic is now known to measure the combined factor VII and X activity. lThromboplastin generation. The thromboplastin generation test, as modified by Hicks and Pitney,24 for determining the thromboplastin generation of whole plasma was used. This test was modified so that two types of generation were done. In the first procedure, the platelet-poor plasma was used and inosithin (soya bean phospholipid) was added as a platelet substitute. This procedure measures the development of plasma or blood thromboplastin. In the second procedure the plateletpoor plasnma was used without the addition of platelets or platelet substitute. The activity developed under these circumstances is similar to the so-called product I.
Heparin tolerance. The procedure as described by Soulier and Le Bolloc'h employing the recalcification of plasma was used25 with no heparin in the first tube and increasing concentrations of heparin in the second to the fourth tubes.
Stypven time. Russell viper venom was diluted 1 to 10,000 with 0.9 per cent saline. Plateleti-poor plasma was diluted two-fold with 0.9 per cent saline; 0.1 ml. of the diluted plate-poor plasma was incubated with 0.1 ml. of freshly prepared Stypven, for one minute at 37 C., then 0.1 ml. of 0.02M calcium chloride was added and the clotting time determined. Fibrinolysis. The fibrinolytic activity of the blood was measured by the euglobulin precipitation method as described by Von Kaulla and Schultz.26 For this procedure 8 ml. of blood were drawn into a syringe containing 2 ml. of 3 per cent sodium citrate. We have found the results of this procedure to he more reproducible than those of the Fearnley whole-blood technic, and Astrup fibrin-plate method. To determine the reproducibility of the results of the euglobulin fibrinolysis, the observations were repeated in 17 subjects and the results were found to be reproducible to within ± 20 per cent. Considering the fact that at present there are no highly reproducible technies for the assay of fibrinolysis, we considered this degree of reproducibility to be satisfactory. Reading of the lysis end points was carried out in the blind fashion by an experienced observer. Analyses were always done in duplicate and the results accepted only if the duplicates were read within /2 hour of each other. The order of sampling from the artery and the vein was alternated whenever possible, and on 10 occasions blood from the artery and the vein was collected simultaneously by two members of the team after a period of equilibration. This procedure was adopted to eliminate the possibility of a misleading conclusion arising from the sampling procedure. In view of the effect of emotional stress, anxiety, fear, etc. on the fibrinolytic activity, so far as possible, subjects were investigated under standardized conditions. Platelet count. The method of Brecher and Cronkite27 was used.
Plasma fibrinogen. The method of Ratnoff and Menzie as modified by Holburn28 was employed.
Hematocrit. The hematocrit value was determined by the microcapillary method.
Statistical studies. In the statistidal analysis of the arteriovenous differences in the same group, the paired-observation method29 was used. In comparing data obtained in studies of blood coagulation and fibrinolysis in different groups, the analysis was carried out by squaring the original values, calculating the sum of squares and standard error of the difference.30 Comparison of the means was carried out by the t test.
Results

Blood Coagulation Studies Arteriovenous Differences in Blood Coagulation
The study of arterial and venous blood in the normal subjects of series A (tables 1 and 2) showed a trend toward lower coagulation activity in the arterial blood as indicated by Quick prothrombin time, Owren prothrombin determination, heparin tolerance test, and thromboplastin generation test with inosithin (platelet substitute). With respect to the Quick prothrombin time, and tubes 3 and 4 of the heparin tolerance test, the differences were statistically significant (table 1) . On the other hand, the thromboplastin generation test without inosithin showed a more rapid evolution of thromboplastin in the arterial blood, but no significant difference in the maximum yield of thromboplastin (table 2) . The study of arterial and venous blood in patients with coronary heart disease of series A (tables 3 and 4) showed no significant differences between the arterial and the venous blood in respect to Quick prothrombin time, any of the specific coagulation factors measured or the thromboplastin generation test without inosithin. The heparin tolerance test in this group again indicated lower coagulation activity in the arterial blood (table 3) , but the arteriovenous differences were less marked than those found in normal subjects.
Differences in Coagulation of Venous Blood between
Normal Subjects and Patients with Coronary Heart
Disease A scattergram of the coagulation results of the control subjects and the patients with coronary heart disease of series B appears in figure 1 . In respect to the hematocrit, the Circulation. Volume XXVII, May 1963 whole blood platelet count, Quick prothrombin time and Owren determination of prothrombin, factor V and factors VII and X, there were no significant differences between the two groups. The Stypven time was shorter in the patients and the differences were statistically significant at the 5 per cent level (table 5) . The thromboplastin generation test with inosithin (platelet substitute) showed a statistically significant increase in the rate of thromboplastin generation in patients with coronary heart disease, compared with the control subjects, but there was no significant difference in the maximum yield of thromboplastin developed ( fig. 2 and table 6 ). The thromboplastin generation test without inosithin showed a more rapid generation as well as a higher maximum yield in patients with coronary heart disease ( fig. 3 ). Both differences were statistically significant (table 6 ). The specific coagulation factor or factors responsible for this increase in thromboplastin generation in patients with coronary heart disease are not clear and we are at present investigating this. the test without the addition of inosithin. In patients with coronary heart disease this arteriovenous difference in thromboplastin generation was absent. Considering the coagulation studies of series A and B together it would appear that the disparity between the arteriovenous differences in thromboplastin generation between the normal subjects and the patients with coronary heart disease is due to increase in the thromboplastin generation of both the arterial and the venous blood in the latter group.
Blood Fibrinolysis Studies
Arteriovenous Differences in Fibrinolysis
An over-all scattergram of the results obtained in both the normal subjects and the patients with atherosclerosis in series A appears in figure 4 . The fibrinolysis time in hours is plotted on the ordinate in 4 columns. Columns 1 and 2 represent the venous and arterial lysis times of the normal subjects, and columns 3 and 4 those of the patients. Each pair of results from the same subject is linked so as better to indicate the arteriovenous dif- 
Mean curves of the thromboplastin generation test
Differences in Fibrinolysis between the Two Groups wcithout the addition of inosithin (platelet substi-I mc thpa tute) the venous blood of control subjects and In comparing the normal subje cts with papat ients with coronary heart disease of series B. tients ( fig. 4) , it is noted that the patients In addition, see table 6. COAGULATION AND FIBRINOLYSIS OF ARTERIALI AND VENOUS BLOOD dition to atherosclerosis, such as hypertension, diabetes mellitus, or hypercholesteremia, whereas others did not. We found no correlation between the presence or absence of these predisposing conditions and the fibrinolytic activity. On the other hand, the relation between the type of clinical manifestation of atheroselerotic disease and fibrinolytic activity seemed more remarkable. In the scatter-gram ( fig. 4 ) some patients are noted as having a particularly prolonged fibrinolysis time. It is of interest that most (ten) of these patients, that is the encireled results, comprise all the relatively young patients in this series who have occlusive disease of the peripheral arteries. Their ages range between 32 and 50 years. To indicate this more clearly, in figure  5 , the arterial lysis times of the patients with The number of observations on which the averages are based appears in parentheses. V, venous average; A, arterial average; SE, standard error of difference; P, probability of the differenee using the t test; CS, control subjects; PAD, patients with atherosclerosis as manifested by angina pectoris, old myocardial infarction, or occlusive disease of the peripheral arteries, or both; CHD, subgroup of patients with coronary heart disease as manifested by angina pectoris or old myocardial infarction; OAD, subgroup of patients with occlusive disease of the peripheral arteries. Encircled results indicate the 10 relatively young patients with occlusive disease of the peripheral arteries. In one of these, no arterial blood was obtained. Results have been corrected to the nearest half hour. Each pair of results has been linked so as better to indicatte the arteriovenous differences and also to point out that the arterial lysis times were almost uniformly longer than the venous. Where two or more pairs of results occur at the same level in both venous and arterial columns, only one line has been drawt to link them. Since on occa!sions no arterial blood was obtained, there are fewer arterial results compared with venous. In the statistical study of the arteriovenous differences, however, only paired results were used. atherosclerosis have been plotted against their ages. The younger patients with occlusive disease of the peripheral arteries are noted to be segregated from the rest of the group because of their long lysis times and relatively young years. In figure 5 there are nine encircled results, since in one of these 10 patients no arterial sample was obtained, but the venous result in that patient, too, indicated very low fibrinolytic activity. It is noteworthy that seveni of 10 of these younger patients with occlusive disease are females. It therefore appears that the low fibrinolytic activity in patients with atherosclerosis was particularly noteworthy in those with occlusive disease of the peripheral arteries. When this subgroup of patients with occlusive disease of the peripheral arteries and the nornmal control group were separately compared, there was a highly significant difference between both the venous atnd the arterial data (table 8) . On the other hand, when this subgroup of patients was exeluded from analysis, and the subgroup of patients with coronary heart disease was separately compared with the normal controls, no statistically significant difference was present between the venous lysis tiines of the two latter groups. However, even in the subgroup with coronary heart disease, the arterial fibrinolysis times were longer and the differences were significant at the 2 per cent level (table 8) .
So far as the blood coagulation studies are concerned, we did not have sufficient data in the subgroup with ocelusive diseases of the Scattergram of the arterial fibrinolysis times of the patients with atherosclerosis of series A plotted against age. Encircled results indicate relatively young patients with occlusive disease of the peripheral arteries. There were 10 of these patients, but in one of them no arterial blood was obtained. To avoid a possibly misleading conclusion, therefore, the coagulation results of these patients have been left out altogether.
In comparing a group of patients whose serum cholesterol was higher than 250 mg. per cent (average 317 32 mg. per cent), and a group of patients whose serum cholesterol was lower than this level (average 187 + 28 mg. per cent), we found no significant difference between the mean fibrinolysis times of the two groups in either the venous or the arterial blood (table 8) .
Discussion
In studies of coagulation of the arterial and venous blood of relatively young normal subjects, there were statistically significant arteriovenous differences in some of the tests employed. The arteriovenous differences, however, were not all in the same direction in that some indicated increased and others decreased coagulation activity of the arterial blood. This finding would emphasize the fallacy of attaching undue significance to a single test in studies of this nature. In pa-tients with coronary heart disease, on the other hand, arteriovenous differences in coagulation were less marked or absent. We were interested in the possibility that the passage of blood over a diseased arterial wall increased its coagulation activity because of the surface characteristics of the atheromatous lesions. The changes in arteriovenous differences in coagulation activity observed in patients with eoronary heart disease, in comparison with relatively young normal subjects, could be interpreted as such a possible effect of these lesions. It is recognized, however, that a number of other factors could contribute to, or entirely account for, this phenomenon.
Comparing the blood coagulation activity of the venous blood in patients with coronary heart disease to that of age-matched controls, we found a significantly shorter Stypven clotting time and increased thromboplastin generation in the former group. The significance of the Stypven time, or clotting time of plasma in the presence of Russell viper venom, as an indicator of coagulation activity is not entirely clear. This venom is known to act as a 'able 8 powerful substitute for tissue thromboplastin and factor VII in the presence of certain lipids.31 A shorter Stypven time in patients with atherosclerosis, therefore, does not necessarily indicate an increase in their intrinsic coagulation activity. This finding of a shorter Stypven time in patients with atherosclerosis confirms the results reported by McDonald and Edgill32 and Mustard.33 The same authors have also reported increased thromboplastin generation in the blood of such patients, and Spittel and Pascuzzi et al.34' 3 have found an increase in a factor they have designated as thromboplastin generation accelerator in patients with atherosclerosis obliterans and thrombosis. In our studies, we found a statistically significant increase in the rate of evolution of thromboplastin in patients with coronary heart disease by both types of tests employed, namely, the tests with and without the addition of inosithin (platelet substitute). Only in the latter test, however, was there a significant increase in the maximum yield of thromboplastin, as well as its rate of evolution. It should be pointed out that our methods differed from those of the other investi-
gators.
There was no significant difference between the whole-blood platelet counts of the control subjects and the patients with atherosclerosis. This finding accords with the results of some investigators32 but contradicts those of others33 who reported a higher platelet count in such patients.
We found some elevation of plasma fibrinogen level in some patients with coronary heart disease but unlike some workers32 we found no statistically significant difference between such patients and normal control subjects in this respect.
Our results therefore indicate some evidence of increased coagulation activity of the blood in patients with coronary heart disease. The available data, however, do not indicate whether this increased coagulation activity is etiologic in the pathogenesis of atherosclerosis, a result of it, or simply an associated finding.
There was generally a lower level of fibrino-lytic activity in the arterial blood as compared to the venous in both the normal subjects and the patients with atherosclerosis. Statistical study in both groups showed this difference to be highly significant. While we know of no reports as to arteriovenous differences in coagulation tests there are two studies of the arteriovenous differences in fibrinolytic activity. Kwaan et al.,36 using the method of Biggs and Maefarlane,37 found no significant arteriovenous differences in three patients with the syndrome of cryptogenic splenomegaly. On the other hand, Fearnley et al. 38 reported a significant arteriovenous difference in five cases in each group of six normal subjects and six patients with atherosclerosis. He reported no significant differences between the two groups.
The arteriovenous difference in fibrinolysis was found to vary widely from one individual to another, particularly in the patients with atherosclerosis. This variability would imply that in studies on fibrinolysis, venous findings may not be taken as a reliable reflection of the fibrinolytic activity of arterial blood. Hence, in studies of fibrinolysis as related to arterial thrombosis, arterial blood samples should be routinely used.
The higher level of fibrinolytic activity found in the venous system in our studies is consistent with the findings of Kwaan et al., 39, 40 who demonstrated by experiments on the isolated ear vein of rabbits, a peripheral venous origin for the release of fibrinolytic activity. More recently, Todd41' 42 has also presented evidence that indicates the possible venous origin of the blood fibrinolytic activity. By means of histologic fibrin-film teehnic, he has shown that the plasminogen activator in the tissue is concentrated around veins, venules, and pulmonary arteries, in close association with their endothelium, whereas little or no activator is evident around systemic arteries.
Considered in the light of the recent advances in the knowledge of coagulation mechanism, this higher level of fibrinolytic activity in the venous system compared to the arterial, Circulation, Volume XXVII, May 1961 may be significant. Many students of coagulation now consider the blood coagulation mechanism to be in a state of dynamic equilibrium, a limited amount of clotting proceeding continually and excessive accumulation of fibrin being prevented by fibrinolysis.43 In the venous system, in view of the sluggish circulation and liability to stagnation, clotting may be expected to proceed more rapidly than in the arterial system. Thus, teleologically, to maintain the delicate coagulation-fibrinolysis equilibrium in the venous system, a more efficient fibrinolytic mechanism would be necessary.
In comparing patients with coronary heart disease to normal subjects, we found a significantly lower fibrinolytic activity in the arterial blood of the patients, but not in the venous. This lack of significant differences between the fibrinolytic activity of the venous blood in patients with coronary heart disease and control subjects confirms the results of Merskey et al. 44 They did not report on the fibrinolytic activity of the arterial blood. It therefore appears that in patients with coronary heart disease there is some evidence of increased blood coagulation activity as well as reduced arterial fibrinolytic activity. Thus, in the delicate dynamic balance of blood coagulation and fibrinolysis in such patients, the scale seems to be tipped in the direction of clot formation. The question naturally arises whether the demonstration of such clotting changes in vitro implies a tendency to thrombosis in vivo.45 In this respect we have found in recent experiments in the rat46 a concurrence between these two parameters albeit without necessarily a cause and effect relationship.
In patients with occlusive disease of the peripheral arteries there was a significantly lower fibrinolytic activity in both the arterial and the venous blood. In this group, the younger patients exhibited the lowest fibrinolytic activity. The reduction in fibrinolytic activity in the blood of the patients with intermittent claudication has been previously noted by Nestel.47 He reported on the fibrino-Circulation, Volume XXVII, May 1963 lysis of the venous blood of a group of patients with a mean age of 60. In our series, however, the predominance of younger patients with very low fibrinolytic activity was especially noteworthy. It appears significant that all of the 10 patients under the age of 50, who had occlusive disease of the peripheral arteries showed a marked reduction in fibrinolytic activity and that seven of these 10 were females. Moreover, five of these 10 had none of the usual predisposing conditions to early development of occlusive arterial disease, namely, diabetes mellitus, hypertension, or hypercholesteremia. One can only speculate at this juncture as to whether this reduction in fibrinolytic activity in such patients is in any way causally related to the disease process. The method of euglobulin precipitation utilized in our studies is primarily a measure of the plasminogen activator in the blood; since most of the inhibitors of the fibrinolytic enzyme system are removed by euglobulin precipitation. The marked prolongation of the fibrinolysis time found in these younger patients with occlusive disease of the peripheral arteries is therefore probably not due to an increase in the inhibitors of the plasminogen enzyme system. We had the opportunity to repeat our studies in one of the younger patients with occlusive disease of the peripheral arteries 10 months after the original observations. There was again a marked reduction in the fibrinolytic activity as measured by the euglobulin method. Furthermore, streptokinase-induced fibrinolysis, measured by a modification of the method of Loomis as used by Nitzberg et al.20 was also reduced. However, there was no increase in antifibrinolysis as measured by the method of Kaplan.48 This finding further strengthens the impression that the prolonged fibrinolysis time in these patients is not due to increase in fibrinolysin inhibitors but may indicate a primary deficiency in one of the basic components of the plasminogen enzyme system.
There was no correlation between serum cholesterol level and fibrinolytic activity. This would support the findings of Nitzberg et al., 20 Hougie 9 Greig,50 and Billimoria.19 It contradicts the findings of Kwaan and MeFadzean,61 who found inhibition of fibrinolysis on feeding cholesterol to rabbits. It is, of course, possible that in their experiment other lipid changes may have been involved.
Summary
In studies of coagulation of the arterial and venous blood of relatively young normal subjects, there were statistically significant arteriovenous differences in some of the tests employed. These differences, however, were not all in the same direction in that some indicated increased and some decreased coagulation activity of the arterial blood. In patients with coronary heart disease, these arteriovenous differences were absent or less marked. It was suggested that this change in arteriovenous difference in such patients could possibly be attributed to the surface effect of the diseased arterial wall on the coagulation mechanism. It was recognized, however, that a number of other factors could contribute to, or entirely account for, this phenomenon.
There was some evidence of increased coagulation activity in the venous blood of patients with coronary heart disease as compared to matched controls. This was indicated bv a more rapid generation of thromboplastin with the addition of inosithin (platelet substitute), and a more rapid generation as well as a greater yield of thromboplastin without the addition of inosithin.
Fibrinolytic activity was significantly lower in the arterial blood compared to the venous in both the normal subjects and patients with atherosclerosis. This arteriovenous difference was greater in the atherosclerotic group and it was widely variable. Because of this variability, venous fibrinolysis determinations could not be taken as an indicator of the level of fibrinolytic activity in the arterial blood. Hence, it was suggested that in studies of fibrinolysis as related to atherosclerosis, arterial blood samples should be routinelv used.
Fibrinolytic activity of the blood in the atherosclerotic group as a whole was lower than that in the normal group on both the arterial and the venous sides. The difference between the two groups was greater in the arterial than the venous blood. In the group with atherosclerosis, the subgroup with coronarv heart disease and that with occlusive disease of the peripheral arteries were separately analyzed. The subgroup with coronary heart disease exhibited a significantly lower fibrinolytic activity compared to normal subjects only in the arterial blood, whereas the subgroup with occlusive disease of the peripheral arteries showed a lower fibrinolytic activity in both the arterial and the venous blood. In the subgroup with occlusive disease of the peripheral arteries, it was particularly noteworthy that the vounger patients had a very low fibrinolytic activitv. It was thought that one could only speculate as to whether this low fibrinolytic activity in such young patients is in any wav causallv related to the disease process.
It appeared that in patients with coronary heart disease the delicate balance of coaoulation and fibrinolysis was tipped in the direetion of clot formation. It was not clear, however, whether the changes in blood coagulation and fibrinolysis observed in such patients were etiologic in the pathogenesis of the disease process, associated with it, or simplv a secondary phenomenon. Moreover, it was recognized that in vitro demonstration of such changes in blood coagulation and fibrinolysis does not necessarily imply in vivo hypercoagulability.
No correlation was found between the level of serum cholesterol and plasma fibrinolytic activity.
On Science and Culture
In nman's history the sciences make changes which cannot be wished away and cannot be undone. Let me give two quite different examples. There is much talk about getting rid of atomic bombs. I like that talk; but we must not fool ourselves. The world will not be the same, no matter what we do with atomic bombs, because the knowledge of how to make them cannot be exorcised. It is there; and all our arrangements for living in a new age must bear in mind its onmipresent virtual presence, and the fact that one cannot change that. A different example: we can never have again the delusions about the centrality and importance of our physical habitat, now that we know something of where the earth is in the solar system, and know that there are hundreds of billions of suns in our galaxy, and hundreds of billions of galaxies within reach of the great telescopes of the world. We can never again base the dignity of man's life on the special character in space and time of the place where he happens to live. These are irreversible changes; so it is that tke cumulative character gives a paradigm of something which is, in other respects, very much more subject to question: the idea of human progress. One cannot doubt that in the sciences the direction of growth is progress. This is true both of the knowledge of fact, the understanding of nature, and the knowledge of skill, of technology, of learning how to do things. When one applies this to the human situation, and complains that we make great progress in automation and computing and space research but no comparable moral progress, this involves a total misunderstanding of the difference between the two kinds of progress. I do not mean that moral progress is impossible; but it is not, in any sense, automatic. Moral regress, as we have seen in our day, is just as possible. Scientific regress is not compatible with the continued practice of science.-J. ROBERT OPPENHEIMER. "On Science and Culture."' Encounter, October, 1962, p. 3.
